孟鲁司特联合布地奈德治疗嗜酸性粒细胞性支气管炎的临床效果研究  

Clinical study on the treatment of eosinophilic bronchitis with montelukast and budesonide

作　　者：曹静 CAO Jing(Xingcheng People's Hospital,Huludao 125100,China)

机构地区：[1]兴城市人民医院,125100

出　　处：《中国现代药物应用》2023年第5期98-100,共3页Chinese Journal of Modern Drug Application

摘　　要：目的研究嗜酸性粒细胞性支气管炎给予孟鲁司特联合布地奈德治疗的临床效果。方法88例嗜酸性粒细胞性支气管炎患者,按照治疗模式不同分为观察组和对照组,每组44例。观察组患者给予孟鲁司特联合布地奈德治疗,对照组患者给予布地奈德治疗。对比两组患者临床症状(声嘶、肺部啰音、咳嗽、憋喘)消失时间,治疗前后肺功能指标[二氧化碳分压(PCO_(2))、氧分压(PO_(2))、呼气峰值流速(PEF)]变化情况,用药不良反应发生情况。结果观察组患者声嘶、肺部啰音、咳嗽、憋喘消失时间分别为(3.55±0.32)、(5.21±1.44)、(4.71±0.86)、(5.28±0.51)d,明显短于对照组的(5.74±0.33)、(6.54±2.48)、(6.63±0.84)、(6.72±0.73)d,差异具有统计学意义(P<0.05)。治疗后,观察组患者PCO_(2)(40.15±10.77)mm Hg(1 mm Hg=0.133 kPa)低于对照组的(49.81±11.34)mm Hg,PO_(2)(86.94±11.88)mm Hg、PEF(4.56±1.04)L/s高于对照组的(76.19±8.97)mm Hg、(3.62±0.95)L/s,差异具有统计学意义(P<0.05)。观察组患者用药不良反应发生率为4.55%(2/44),低于对照组的18.18%(8/44),差异具有统计学意义(P<0.05)。结论采用孟鲁司特联合布地奈德治疗嗜酸性粒细胞性支气管炎患者,可缩短临床症状消失时间,改善肺功能,且用药安全,值得临床推广应用。Objective To study the clinical effect of montelukast combined with budesonide in the treatment of eosinophilic bronchitis.Methods A total of 88 patients with eosinophilic bronchitis were divided into observation group and control group according to different treatment modes,with 44 patients in each group.Patients in the observation group were treated with montelukast and budesonide,and patients in the control group were treated with budesonide.Both groups were compared in terms of time to disappearance of clinical symptoms(hoarseness,pulmonary rales,cough and breathlessness),changes of pulmonary function indexes[partial pressure of carbon dioxide(PCO_(2)),partial pressure of oxygen(PO_(2)),peak expiratory flow rate(PEF)]before and after treatment,and the occurrence of adverse drug reactions.Results The time to disappearance of hoarseness,pulmonary rales,cough and breathlessness in the observation group were(3.55±0.32),(5.21±1.44),(4.71±0.86)and(5.28±0.51)d,which was significantly shorter than(5.74±0.33),(6.54±2.48),(6.63±0.84)and(6.72±0.73)d in the control group,and the differences were statistically significant(P<0.05).After treatment,PCO_(2)(40.15±10.77)mm Hg(1 mm Hg=0.133 kPa)of the observation group was lower than(49.81±11.34)mm Hg of the control group;PO_(2)(86.94±11.88)mm Hg and PEF(4.56±1.04)L/s of the observation group were higher than(76.19±8.97)mm Hg and(3.62±0.95)L/s of the observation group;the differences were statistically significant(P<0.05).The incidence of adverse drug reactions was 4.55%(2/44)in the observation group,which was lower than 18.18%(8/44)in the control group,and the difference was statistically significant(P<0.05).Conclusion Montelukast combined with budesonide for patients with eosinophilic bronchitis can shorten the disappearance time of clinical symptoms,improve the lung function of patients with medication safety,which is worthy of clinical promotion and application.

关 键 词：嗜酸性粒细胞支气管炎 孟鲁司特 布地奈德 可行性 

分 类 号：R562.21[医药卫生—呼吸系统]